Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms Near

TOKYO - Eisai March 31 said it had applied for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare; U.S. FDA and the European Medicines Agency for eribulin for the treatment of locally advanced and metastatic breast cancer